Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03BLF
|
|||
| Former ID |
DAP000417
|
|||
| Drug Name |
Triamcinolone
|
|||
| Synonyms |
Adcortyl; Aristocort; Celeste; Cinolone; Delphicort; Fluoxiprednisolone; Fluoxyprednisolone; Fougera; Ione; Kenacort; Ledercort; Mycolog; Omcilon; Omicilon; Orion; Rodinolone; Tiamcinolonum; Triamcet; Triamcinalone; Triamcinlon; Triamcinolon; Triamcinolona; Triamcinolonum; Tricortale; Trilone; Tristoject; Volon; Aristocort Tablets; Triamcinolonum [INN]; CL 19823; Aristocort (TN); Azmacort (TN); Cinolone-T; Fougera (TN); Kenacort (TN); Kenacort-AG; Kenalog (TN); Nasacort (TN); SK-Triamcinolone; Tiamcinolonum [INN-Latin]; Triam-Tablinen; Triamcinolona [INN-Spanish]; Tricortone (TN); Triderm (TN); Triesence (TN); Trilone (TN); Tristoject (TN); Volon A (TN); Tri-Nasal (TN); Triamcinolone (JP15/USP/INN); Triamcinolone [USAN:INN:BAN:JAN]; Droxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dio; TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7)); Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-(8CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha); (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione; 11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d; 9.Alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-16alpha-hydroxyprednisolone
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Allergic rhinitis [ICD-11: CA08.0] | Approved | [1] | |
| Therapeutic Class |
Antiinflammatory Agents
|
|||
| Company |
Aventis Pharmaceuticals Inc.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H27FO6
|
|||
| Canonical SMILES |
CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O
|
|||
| InChI |
1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1
|
|||
| InChIKey |
GFNANZIMVAIWHM-OBYCQNJPSA-N
|
|||
| CAS Number |
CAS 124-94-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
77851, 220066, 855586, 7847451, 7980827, 8172093, 10321448, 11405145, 11466148, 11467268, 11485815, 12161841, 14903260, 16626033, 17405735, 24278749, 26746565, 26751455, 34673459, 46507950, 47193900, 47515606, 47662557, 47662558, 47960036, 48035423, 48185265, 49698357, 49854879, 50103941, 50103942, 50103943, 53778285, 53789365, 57311162, 78804372, 81093215, 85787891, 90341396, 92125106, 92303210, 92309068, 92717063, 93576920, 103520216, 103913942, 104253432, 104310562, 117567345, 121362003
|
|||
| ChEBI ID |
CHEBI:9667
|
|||
| ADReCS Drug ID | BADD_D02271 | |||
| SuperDrug ATC ID |
A01AC01; C05AA12; D07AB09; D07XB02; H02AB08; R01AD11; R03BA06; S01BA05
|
|||
| SuperDrug CAS ID |
cas=000124947
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucocorticoid receptor (NR3C1) | Target Info | Modulator | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | |||
| Signaling events mediated by HDAC Class II | ||||
| FOXA2 and FOXA3 transcription factor networks | ||||
| Glucocorticoid receptor regulatory network | ||||
| Regulation of Androgen receptor activity | ||||
| AP-1 transcription factor network | ||||
| Reactome | BMAL1:CLOCK,NPAS2 activates circadian gene expression | |||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
| SIDS Susceptibility Pathways | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Endoderm Differentiation | ||||
| Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | ||||
| Adipogenesis | ||||
| Circadian Clock | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.